Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

Fig. 2

Percentage change from baseline in VLDL-C, remnant cholesterol and TGs with evolocumab vs placebo in participants with high TGs with or without AD on background statin therapy. All treatment differences between evolocumab and placebo are statistically significant at P < 0.0001 except for VLDL-C in the group with high TGs and normal HDL-C (P = 0.0002). HDL-C high-density lipoprotein cholesterol, TG triglycerides, VLDL-C very low-density lipoprotein cholesterol

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840